These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 32124242)
1. DNA damage response proteins and its role in tumor progression of uveal melanoma with patient outcome. Kashyap S; Jha J; Singh MK; Singh L; Sen S; Kaur J; Bajaj MS; Pushker N Clin Transl Oncol; 2020 Sep; 22(9):1472-1480. PubMed ID: 32124242 [TBL] [Abstract][Full Text] [Related]
2. Prognostic relevance of ATM protein in uveal melanoma and its association with clinicopathological factors. Jha J; Singh MK; Singh L; Pushker N; Bajaj MS; Sen S; Kashyap S Int J Clin Oncol; 2019 Dec; 24(12):1526-1535. PubMed ID: 31377937 [TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma. Staby KM; Gravdal K; Mørk SJ; Heegaard S; Vintermyr OK; Krohn J Acta Ophthalmol; 2018 Feb; 96(1):31-38. PubMed ID: 28444874 [TBL] [Abstract][Full Text] [Related]
4. Expression of BAP1 and ATM proteins: Association with AJCC tumor category in uveal melanoma. Jha J; Singh MK; Singh L; Pushker N; Bajaj MS; Sen S; Kashyap S Ann Diagn Pathol; 2020 Feb; 44():151432. PubMed ID: 31864162 [TBL] [Abstract][Full Text] [Related]
5. Association of TYRP1 with hypoxia and its correlation with patient outcome in uveal melanoma. Jha J; Singh MK; Singh L; Pushker N; Lomi N; Meel R; Chosdol K; Sen S; Bakhshi S; Kashyap S Clin Transl Oncol; 2021 Sep; 23(9):1874-1884. PubMed ID: 33811629 [TBL] [Abstract][Full Text] [Related]
6. Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma. Koopmans AE; Verdijk RM; Brouwer RW; van den Bosch TP; van den Berg MM; Vaarwater J; Kockx CE; Paridaens D; Naus NC; Nellist M; van IJcken WF; Kiliç E; de Klein A Mod Pathol; 2014 Oct; 27(10):1321-30. PubMed ID: 24633195 [TBL] [Abstract][Full Text] [Related]
7. BAP1 protein loss by immunohistochemistry: a potentially useful tool for prognostic prediction in patients with uveal melanoma. Shah AA; Bourne TD; Murali R Pathology; 2013 Dec; 45(7):651-6. PubMed ID: 24247622 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Germline versus Somatic BAP1 Mutations for Risk of Metastasis in Uveal Melanoma. Ewens KG; Lalonde E; Richards-Yutz J; Shields CL; Ganguly A BMC Cancer; 2018 Nov; 18(1):1172. PubMed ID: 30477459 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value of chromosomal imbalances, gene mutations, and BAP1 expression in uveal melanoma. Patrone S; Maric I; Rutigliani M; Lanza F; Puntoni M; Banelli B; Rancati S; Angelini G; Amaro A; Ligorio P; Defferrari C; Castagnetta M; Bandelloni R; Mosci C; DeCensi A; Romani M; Pfeffer U; Viaggi S; Coviello DA Genes Chromosomes Cancer; 2018 Aug; 57(8):387-400. PubMed ID: 29689622 [TBL] [Abstract][Full Text] [Related]
10. Correlation of Immunocytochemistry of BRCA1-associated Protein-1 (BAP1) With Other Prognostic Markers in Uveal Melanoma. Glasgow BJ; McCannel TA Am J Ophthalmol; 2018 May; 189():122-126. PubMed ID: 29530782 [TBL] [Abstract][Full Text] [Related]
11. Uveal Melanoma Nuclear BRCA1-Associated Protein-1 Immunoreactivity Is an Indicator of Metastasis. Szalai E; Wells JR; Ward L; Grossniklaus HE Ophthalmology; 2018 Feb; 125(2):203-209. PubMed ID: 28823399 [TBL] [Abstract][Full Text] [Related]
12. ITGB2-ICAM1 axis promotes liver metastasis in BAP1-mutated uveal melanoma with retained hypoxia and ECM signatures. Li J; Cao D; Jiang L; Zheng Y; Shao S; Zhuang A; Xiang D Cell Oncol (Dordr); 2024 Jun; 47(3):951-965. PubMed ID: 38150154 [TBL] [Abstract][Full Text] [Related]
14. BAP1 Loss Is Associated with DNA Methylomic Repatterning in Highly Aggressive Class 2 Uveal Melanomas. Field MG; Kuznetsov JN; Bussies PL; Cai LZ; Alawa KA; Decatur CL; Kurtenbach S; Harbour JW Clin Cancer Res; 2019 Sep; 25(18):5663-5673. PubMed ID: 31285370 [TBL] [Abstract][Full Text] [Related]
15. Prognostic parameters in uveal melanoma and their association with BAP1 expression. van Essen TH; van Pelt SI; Versluis M; Bronkhorst IH; van Duinen SG; Marinkovic M; Kroes WG; Ruivenkamp CA; Shukla S; de Klein A; Kiliç E; Harbour JW; Luyten GP; van der Velden PA; Verdijk RM; Jager MJ Br J Ophthalmol; 2014 Dec; 98(12):1738-43. PubMed ID: 25147369 [TBL] [Abstract][Full Text] [Related]
17. Transposase mapping identifies the genomic targets of BAP1 in uveal melanoma. Yen M; Qi Z; Chen X; Cooper JA; Mitra RD; Onken MD BMC Med Genomics; 2018 Nov; 11(1):97. PubMed ID: 30400891 [TBL] [Abstract][Full Text] [Related]
18. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. Abdel-Rahman MH; Pilarski R; Cebulla CM; Massengill JB; Christopher BN; Boru G; Hovland P; Davidorf FH J Med Genet; 2011 Dec; 48(12):856-9. PubMed ID: 21941004 [TBL] [Abstract][Full Text] [Related]
19. Verification of EZH2 as a druggable target in metastatic uveal melanoma. Jin B; Zhang P; Zou H; Ye H; Wang Y; Zhang J; Yang H; Pan J Mol Cancer; 2020 Mar; 19(1):52. PubMed ID: 32127003 [TBL] [Abstract][Full Text] [Related]
20. Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing. Kalirai H; Dodson A; Faqir S; Damato BE; Coupland SE Br J Cancer; 2014 Sep; 111(7):1373-80. PubMed ID: 25058347 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]